Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Phase 4 Completed 43 enrolled Astellas Pharma Inc

Non-randomizedSingle-groupOpen-labelPrevention

Summary

A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Timeline

Start: 2007-07
Primary completion: 2008-07
Completion: 2008-07

Publications

Background Lynde C, Krell J, Korman N, Mathes B; Vaccine Study Investigators. Immune response to pneumococcal polysaccharide vaccine in adults with chronic plaque psoriasis treated with alefacept. J Am Acad Dermatol. 2011 Oct;65(4):799-806. doi: 10.1016/j.jaad.2010.04.040. Epub 2011 Mar 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pneumovax 23	Vaccine	—	Other
Background	Alefacept	Protein / enzyme biologic	—	Intramuscular

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Summary

Timeline

Publications

Drugs

Indications